Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In a recent preclinical study, scientists used a semaglutide-loaded microneedle patch in obese mice and observed comparable plasma drug concentrations to subcutaneous injection, along with improvements in glucose tolerance and reduced food intake
My Approach When Prescribing Here's my general framework not a rigid protocol, but a starting point for the conversation: I Tend to Start with Semaglutide When The patient has established cardiovascular disease (because of the SELECT trial data) Insurance covers semaglutide but not tirzepatide The patient has MASH/fatty liver disease Cost is the primary concern and semaglutide is more accessible I Tend to Start with Tirzepatide When Maximum weight loss is the primary goal The patient has type 2 diabetes (tirzepatide shows greater A1C reduction roughly 2.02.5% vs 1.02.0% for semaglutide) The patient has tried semaglutide with insufficient results Insurance covers both options equally Regardless of which medication we choose, I always emphasize that GLP-1 therapy is most effective when combined with nutritional counseling, physical activity, and behavioral support
Dissolving microneedle-assisted long-acting Liraglutide delivery to control type 2 diabetes and obesity
Participants in clinical trials showed average A1C improvements continuing to accumulate through month six
US$ 21.86
US$ 25.29
US$ 29.89
US$ 21.40
